The size of the Global Ophthalmology Therapeutics Market was worth USD 25.72 billion in 2019 and estimated to be growing at a CAGR of 7.4%, to reach USD 36.75 billion by 2024 during the forecast period 2019 - 2024.
The market is showcasing the evident potential in the mentioned forecasting period. Ophthalmology is the branch of medicine associated with the treatment of eye defects and diseases. With the recent advancements in genetics and stem cell biology, the mechanisms of many ophthalmic diseases are being revealed progressively.
The global market for Ophthalmology Therapeutics is driven by the growing prevalence of vision impairment, which was estimated to be 147 million in 2010, and is estimated to reach 191 million in the world in 2020. Technological advancement in the field of medicine is also playing a major role in the growth of the market. Increasing the geriatric population around the globe along with the rise in disposable income are some of the other factors driving the market for the Ophthalmology Therapeutics Market.
However, lack of awareness about the various diseases associated with ophthalmology is a major factor restraining the growth of the market. Stringent regulatory framework and unclear reimbursement policies are also acting as hurdles for market growth.
REPORT COVERAGE:
|
REPORT METRIC |
DETAILS |
|
Market Size Available |
2018 – 2024 |
|
Base Year |
2018 |
|
Forecast Period |
2019 - 2024 |
|
Segments Covered |
By Basis of Indication, End User and Region |
|
Various Analyses Covered |
Global, Regional & Country Level Analysis, Segment-Level Analysis, DROC, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities |
|
Regions Covered |
North America, Europe, APAC, Latin America, Middle East & Africa |
|
Market Leaders Profiled |
Pfizer Inc., Allergan Inc., Alcon Inc., Merck & co. Inc., Roche Valeant, Regeneron, Santen, Bayer, Senju, Lpath and Eye Gate Pharmaceuticals |
This research report on the Global Ophthalmology Therapeutics Market has been segmented and sub-segmented into the following categories and analyzed market size & forecast for each segment until 2024.
Ophthalmology Therapeutics Market Analysis - By Basis of Indication:
Based on basis of indication, the Glaucoma segment is the largest indication segment accounting for a share of approximately 31% followed by AMD with a share of 27%.
Ophthalmology Therapeutics Market Analysis - By End User:
Regional Analysis:
North America is the dominating market for Ophthalmology Therapeutics accounting for a share of approximately xx% followed by Europe. Asia-Pacific is estimated to be the fastest-growing region with a CAGR of xx% during the forecast period of 2019 - 2024.
Prominent companies leading the Global Ophthalmology Therapeutics Market profiled in the report are:
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 By Indication
5.1.1 Glaucoma
5.1.2 Dry Eye Syndrome
5.1.3 Diabetic Retinopathy
5.1.4 Retinal Vein Occlusion
5.1.5 Age-Related Macular Degeneration (AMD)
5.1.6 Macular Edema
5.1.7 Allergic Conjunctivitis
5.2 By End User
5.2.1 Hospitals
5.2.2 Eye Clinics
5.2.3 Diagnostic Centers
5.2.4 Patients
6. Geographical Analysis
6.1 North America
6.1.1 Introduction
6.1.2 United States
6.1.3 Canada
6.2 Europe
6.2.1 Introduction
6.2.2 U.K
6.2.3 Spain
6.2.4 Germany
6.2.5 Italy
6.2.6 France
6.3 Asia-Pacific
6.3.1 Introduction
6.3.2 China
6.3.3 India
6.3.4 Japan
6.3.5 South Korea
6.3.6 Australia
6.4 Latin America
6.4.1 Introduction
6.4.2 Brazil
6.4.3 Argentina
6.4.4 Mexico
6.5 Middle East & Africa
6.5.1 Introduction
6.5.2 Middle-East
6.5.3 Africa
7. Pipeline Product Analysis
7.1 Overview
7.2 Pipeline Development Landscape
7.3 Molecular Targets in the Pipeline
7.4 Clinical Trials
7.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target
7.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target
7.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target
8.Strategic Analysis
8.1 PESTLE analysis
8.1.1 Political
8.1.2 Economic
8.1.3 Social
8.1.4 Technological
8.1.5 Legal
8.1.6 Environmental
8.2 Porter’s Five analysis
8.2.1 Bargaining Power of Suppliers
8.2.2 Bargaining Power of Consumers
8.2.3 Threat of New Entrants
8.2.4 Threat of Substitute Products and Services
8.2.5 Competitive Rivalry within the Industry
9.Market Leaders' Analysis
9.1 Allergan, Inc.
9.1.1 Overview
9.1.2 Product Analysis
9.1.3 Financial analysis
9.1.4 Recent Developments
9.1.5 SWOT analysis
9.1.6 Analyst View
9.2 Merck & Co Inc
9.3 Pfizer
9.4 Roche
9.5 Novartis (Alcon)
9.6 Valeant
9.7 Regeneron
9.8 Santen
9.9 Bayer
9.10 Senju
9.11 Lpath
9.12 Eye Gate Pharmaceuticals
10.Competitive Landscape
10.1 Market share analysis
10.2 Merger and Acquisition Analysis
10.3 Agreements, collaborations and Joint Ventures
10.4 New Product Launches
11.Market Outlook & Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
Feb 2020
Download Sample
Feb 2020
Download Sample
Feb 2020
Download Sample
Feb 2020
Download Sample
Feb 2020
Download Sample
